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Myotonic dystrophy 2 (DM2) is a multisystem skeletal
muscle disease caused by an expansion of tetranucle-
otide CCTG repeats, the transcription of which results
in the accumulation of untranslated CCUG RNA. In
this study, we report that CCUG repeats both bind to
and misregulate the biological functions of cytoplas-
mic multiprotein complexes. Two CCUG-interacting
complexes were subsequently purified and analyzed.
A major component of one of the complexes was
found to be the 20S catalytic core complex of the
proteasome. The second complex was found to con-
tain CUG triplet repeat RNA-binding protein 1
(CUGBP1) and the translation initiation factor eIF2.
Consistent with the biological functions of the 20S
proteasome and the CUGBP1-eIF2 complexes , the
stability of short-lived proteins and the levels of the
translational targets of CUGBP1 were shown to be
elevated in DM2 myoblasts. We found that the over-
expression of CCUG repeats in human myoblasts
from unaffected patients , in C2C12 myoblasts , and
in a DM2 mouse model alters protein translation
and degradation, similar to the alterations observed
in DM2 patients. Taken together , these findings
show that RNA CCUG repeats misregulate protein
turnover on both the levels of translation and pro-
teasome-mediated protein degradation. (Am J
Pathol 2009, 175:748–762; DOI: 10.2353/ajpath.2009.090047)
Myotonic dystrophy 2 (DM2) is a muscular disease clin-
ically similar to but distinct from DM1. Both diseases are
multisystemic and are characterized by significant clini-
cal heterogeneity.1,2 Like DM1, DM2 pathology is asso-
ciated with cataracts, myotonia, and cerebral, endocrine,
and cardiac abnormalities.2 DM1 is caused by untrans-
lated polymorphic CTG triplet repeats in the 3 untrans-
lated region of the myotonin protein kinase gene on
chromosome 19q.3 The mutation causing DM2 is an
expansion of an untranslated tetranucleotide CCTG re-
peat in the first intron of the ZNF9 gene on chromosome
3q.4 The identification of untranslated CCTG repeats as
the causative mutation in DM2 suggests similarity of clin-
ical symptoms in both diseases. However, there are sev-
eral important differences. Unlike DM1 patients, DM2
patients show predominantly proximal muscle weakness
and only moderate muscle wasting.2,5 In addition, clinical
myotonia in DM2 is usually milder than in DM1. An im-
portant distinction of DM2 is the lack of a congenital form
of the disease. In DM1, very long CTG repeats (more than
800) lead to the most severe form of disease, congenital
DM1, which is associated with significant delay of muscle
development, neonatal weakness and mental retarda-
tion.1 Although DM2 patients have much larger expan-
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sions of repeats, there are no known cases of congenital
disease.
Examinations of molecular mechanisms of DM1 sug-
gested that untranslated CTG repeats cause the disease
through RNA CUG repeats,6–9 which bind to and misregu-
late RNA CUG-binding proteins CUGBP1 andMBNL1.10–12
Studies of mousemodels indicated that the main symptoms
of DM1 (myotonia and muscular dystrophy) are due to a
CUG RNA-mediated mechanism7–9 associated with an in-
crease of CUGBP19,13,14 and with a reduction of MBNL1.15
CUGBP1 has several functions in RNA metabolism, includ-
ing translation,16–18 splicing,19,20 and regulation of RNA
stability21, whereas MBNL is a splicing regulator.15,22
To determine molecular pathways by which RNA
CCUG repeats cause DM2 pathology, we have examined
the hypothesis that RNA CCUG repeats target large pro-
tein-protein complexes in the cytoplasm of DM2 cells. We
found that RNA CCUG repeats interact with two cytoplas-
mic multiprotein complexes and that the amounts of
these complexes are increased in the cytoplasm of DM2
myoblasts. One of these complexes is the CUGBP1-eIF2
complex.17 This complex interacts with CCUGn RNA re-
peats in the livers of CCTG transgenic mice and in the
cytoplasm of C2C12 myoblasts transfected with long
CCTG repeats. A major component of a second CCUG-
binding complex is the 20S core complex of the protea-
some. Consistent with the biological functions of these
complexes, protein levels of CUGBP1-regulated transla-
tional targets and the stability of short-lived proteins are
increased in DM2 muscle cells. Ectopic expression of
RNA CCUG repeats in control myoblasts derived from
unaffected patients changes protein turnover similar to
alterations observed in DM2 myoblasts.
Materials and Methods
Tissue Culture and Western Blot Analysis
C2C12 mouse myoblasts were grown at 5% CO2 in the
growth medium consisting of Dulbecco’s modified Ea-
gle’s medium, 10% fetal bovine serum, and 100 g/ml
penicillin/streptomycin. Myoblast fusion was induced by
switching of growth medium to differentiation medium.
Fusion medium contained Dulbecco’s modified Eagle’s
medium, supplemented with 2% horse serum, 0.01 mol/L
insulin, 2 mmol/L glutamine, and 2.5 mol dexametha-
sone. Cells were maintained in fusion medium for 5 days
with daily change of medium and formation of myotubes
was monitored microscopically.
Human primary myoblast cultures were established
from muscle biopsies of unaffected individuals and DM2
patients. Human myoblasts were grown at 50% density in
Ham’s F-10 medium containing 15% fetal bovine serum,
5% defined supplemented calf serum, 2 mmol/L L-glu-
tamine, and 100 g/ml penicillin/streptomycin.
Nuclear and cytoplasmic extracts were prepared as
described.16,18 Western blotting was performed with rab-
bit polyclonal anti-eIF2 (FL-315), rabbit polyclonal anti-
eIF2 (H-203), rabbit polyclonal anti-MEF2A (H-300),
rabbit polyclonal anti-C/EBP (C19), mouse monoclonal
anti-HuR (3A2), rabbit polyclonal anti-p21 (H164), mouse
monoclonal anti-CUGBP1 (3B1), mouse monoclonal anti-
Hsp70 (3A3), rabbit polyclonal anti-CRT (H-170), rabbit
polyclonal anti-c-myc (N 262) (all from Santa Cruz Bio-
technology Inc., Santa Cruz, CA), and with mouse mono-
clonal anti--actin (AC-15) (Sigma) as recommended by
manufacturers. The antibodies to the 20S core of the
proteasome were as follows: mouse monoclonal anti-sub-
unit 2 (MCP21), mouse monoclonal anti-4 (MCP34),
mousemonoclonal anti-6 (MCP106), andmousemonoclo-
nal anti-7 (MCP72) (all from Affinity Research Products/
Biomol International, Devon, United Kingdom, LP). To de-
tect mono- and polyubiquitinylated conjugates, monoclonal
antibodies FK-2 (Biomol International, Devon, United King-
dom, LP) were used according to the protocol from the
manufacturer.
CCTG Transgenic (TR) Mice and Isolation of
Proteins from the Liver
CCTG TR mice expressing non-coding CCUG121 repeats
in several tissues, including liver, were generated and char-
acterized in the laboratory of Dr. Krahe (M.D. Anderson
Cancer Center, Houston, TX). Expression of expanded
CCUG121 repeats in thesemice caused themain symptoms
of DM2 (M. Sirito, M. Wojciechowska, L.L. Bachinski, O.
Raheem, C. Huichalaf, B.H.G. Schoser, D.R. Mosier, K.A.
Sheikh, G. Zhang, P. Mancias, C.S. Van Pelt, L. Timchenko,
B. Udd, and R. Krahe, manuscript in preparation). Livers
were harvested from 6-month-old wild-type and CCTG TR
mice. Cytoplasmic and nuclear extracts were isolated by
homogenization of the liver in buffer A containing 20mmol/L
Tris-HCl, pH 7.5, 30mmol/L KCl, 5mmol/L dithiothreitol, and
10% glycerol and phosphatase inhibitors. Following centrif-
ugation, the supernatant (cytoplasm) was frozen and stored
at 80°C. Nuclear extracts were isolated by incubation of
the pellet (nuclei) with high salt buffer B containing 20
mmol/L Tris-HCl, pH 7.5, 0.42 mol/L NaCl, 5 mmol/L dithio-
threitol, inhibitors of proteases and phosphatases, and 25%
sucrose.
Electrophoretic Mobility Shift Assay (EMSA) and
UV Cross-Link Assays
EMSA assay and UV cross-link were performed as de-
scribed.16 For EMSA, the sequences of RNA CUG and
CCUG probes are shown in Figure 1. The sequences of
RNA p21 and C/EBP RNA probes were described pre-
viously.16,17 The sequence of control AU-rich c-fos RNA
was as follows: 5-UAUUUAUAUUUUUAUUUUAUUU-3.
RNA probes were labeled by [32P]ATP with T4 kinase
and incubated with cytoplasmic proteins (20 g) from
cultured cells (C2C12 myotubes, human primary myo-
blasts derived from unaffected patients and from patients
with DM2), or from mouse liver. The incubation buffer
contained 20 mmol/L Tris-HCl, pH 7.5, 100 mmol/L KCl, 5
mmol/L dithiothreitol, 100 ng of tRNA, and phosphatase
inhibitors. The binding reactions were resolved by native
5% polyacrylamide gel electrophoresis. The gel was
dried and autographed with X-ray film.
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UV Cross-Link Assay
The purified proteins (CUGBP1 fused with maltose-bind-
ing protein, complex 3–2, or 20S and 26S proteasomes)
or various protein extracts were incubated with RNA
probes as described for EMSA assay. Where indicated,
specific non-radioactive RNA competitors (100 ng) or
specific antibodies (1 g), were added before radioac-
tive probe addition. After incubation, the binding reac-
tions were treated with UV light and resolved by denatur-
ing 4 to 20% polyacrylamide gel electrophoresis. The
proteins were transferred on membrane and exposed to
X-ray film. The membranes were stained with Coomassie
blue to verify protein loading.
Inhibition of Proteasome Activity
To determine formation of ubiquitin conjugates of total
proteins and conjugates of p21, proteasome activity was
inhibited by MG132 (Biomol International, Devon, United
Kingdom, LP). The cells were treated with 10 mol/L
Figure 1. CCUG RNA repeats form RNA-protein complexes in the cytoplasm of myoblasts derived from DM2 patients. A: FISH hybridization detects CCUG
RNA (green) in cytoplasm and in nuclei. The fluorescence in situ hybridization assay was performed with myoblasts from unaffected patients (control) and
with myoblasts from DM2 patients. Bottom images show DAPI staining. Arrows show cytoplasmic foci generated by the expanded CCUG repeats. B:
Northern blot analysis of RNA isolated from cytoplasm and from nuclei of normal (N) and DM2 myoblasts with CAGG16 probe. Bottom images show
ethidium bromide staining of the gels. The 28S and 18S ribosomal RNAs show equal loading and integrity of the used RNAs. C: Detection of RNA CCUG
repeats in nuclear and cytoplasmic RNAs of DM2 myoblasts by dot-blot hybridization. RNA, 5, 10, and 20 g, were loaded on the filter and hybridized with
CAGG16 probe. D: CUG and CCUG RNAs contain common elements, GC islands (shown in red). E: CCUG16 RNA forms three RNA-protein complexes with
cytoplasmic extracts from C2C12 myotubes. EMSA was performed with cytoplasmic proteins isolated from C2C12 myotubes with CUG8, CCUG8, and
CCUG16 probes, shown on the top of the gel. Arrows show three RNA-protein complexes formed with CCUG16 RNA. F: Complexes 1 and 2 contain
CUGBP1. Increasing amounts of non-radioactive CCUG16 probe and Abs to CUGBP1 were incorporated in the binding reactions with cytoplasm and
32P-CCUG16 probe. G: Homogenous MBP-CUGBP1 binds to CCUG RNA. UV cross-link was performed with CUG8, CCUG8, and CCUG16 probes. The filter
was stained with Coomassie blue to verify equal loading of the MBP-CUGBP1. H: CUGBP1 binds to the long CCUG RNA. Increasing amounts of CUGBP1
were incubated with the long CCUG300 probe, treated with UV, and separated by denaturing gel. Upper image shows radioactive signals; the bottom image
shows Coomassie stain of the same membrane. I: Amounts of high molecular weight complex 3 are increased in cytoplasm of DM2 patients. Cytoplasmic
protein extracts from myoblasts derived from unaffected patients (control) and DM2 patients were examined by EMSA with CCUG16 probe. The bottom
image shows results of EMSA analysis. Positions of high molecular weight complex 3 and free probe are shown by arrows. Upper panel shows a Coomassie
stain of the fragment of independent gel with the same loadings of the cytoplasmic proteins as used for the EMSA.
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MG132 for 4 hours and protein extracts were isolated as
described above. Proteins were separated by denatur-
ing 4 to 20% polyacrylamide gel electrophoresis, trans-
ferred onto the membrane, and probed with mono-
clonal antibodies to ubiquitin (clone FK-2, Biomol
International, Devon, United Kingdom, LP). To deter-
mine p21-ubiquitin conjugates, p21 was immunopre-
cipitated from these extracts and examined by Western
blotting with antibodies to ubiquitin. The membranes
were stained with Coomassie blue to verify loading of
IgGs.
Examination of Protein Half-Life
Three different sets of experiments were used to deter-
mine the half-life of proteins. In the first set of experi-
ments, human primary myoblasts from unaffected pa-
tients and from patients with DM2 were maintained in
growth medium. In second set, primary human myoblasts
derived from unaffected patients were transfected with
non-coding synthetic RNAs containing AU repeats
(AU42) and CCUG repeats (CCUG16) using Amaxa bio-
systems cell line Nucleofector kit (Amaxa Biosystems,
Cologne, Germany). In the third set, C2C12 myoblasts
were transfected with AU42 and CCUG16 RNAs. AU42
and CCUG16 RNAs were synthesized in Integrated DNA
Technologies (Coralville, IA). Myoblasts in all three cases
were treated with 10 mmol/L cycloheximide for 30 min-
utes, 1, 2, and 4 hours. Protein extracts were isolated and
examined by Western blotting with antibodies to p21,
c-myc, C/EBP and CUGBP1. In the first set of experi-
ments, 20 g of proteins from DM2 myoblasts and 50 g
of proteins from control myoblasts were used for Western
blotting to adjust for the increase of p21, c-myc, and
CUGBP1 in DM2 myoblasts. Each membrane was re-
probed with -actin, and the levels of protein were cal-
culated as ratios to -actin and then as percentages of
the 0 time point. A summary of three to four independent
experiments is shown.
RNA Dot-Blot Hybridization and Northern
Blotting
Cytoplasmic and nuclear extracts were prepared from con-
trol and DM2 myoblasts following RNA extraction with gua-
nidine thiocyanate. For dot-blot hybridization increasing
amounts of RNA were loaded onto a nylon membrane,
treated by UV light, and hybridized with 32P-(CAGG)16
probe labeled by [32P]ATP.
Northern Blotting
RNA was loaded on a formaldehyde-agarose gel, trans-
ferred onto a nylon membrane, and incubated with
CAGG16 probe. The pictures of 28S and 18S RNAs were
taken from the gels before transfer and used to determine
the integrity of the isolated RNAs.
Fluorescence in Situ Hybridization Assay and IF
Analysis
Control and DM2 primary myoblasts were fixed with 3.7%
formaldehyde in 1X phosphate-buffered saline contain-
ing 5 mmol/L MgCl2. After washing in 1X phosphate-
buffered saline, slides were subjected to prehybridization
in a solution of 40% formamide and 2X standard saline
citrate for 10 minutes at room temperature. Hybridization
solution contained 40% formamide, 2X standard saline
citrate, 10% dextran sulfate, 0.2% bovine serum albumin,
2 mmol/L vanadyl adenosine complex, 1 mg/ml tRNA,
200 g/ml salmon sperm DNA, and 2 g/ml FITC
-labeled CAGG16 probe. After hybridization for 2 hours at
37°C, slides were washed with 1X phosphate-buffered
saline and incubated with primary antibodies (mouse
monoclonal anti-4 of the 20S proteasome, clone
MCP34, Biomol International, Devon, United Kingdom,
LP) in 1X phosphate-buffered saline containing 0.2% bo-
vine serum albumin for 1 hour and then with secondary
antibodies (tetramethylrhodamine B isothiocyanate-con-
jugated goat anti-mouse IgGs from Santa Cruz Biotech-
nologies Inc., Santa Cruz, CA) in 1X phosphate-buffered
saline with 0.2% bovine serum albumin. Slides were
stained with DAPI and mounted in Vectashield medium.
Purification of Protein-Protein Complexes that
Interact with CCUG Repeats
The high molecular weight (MW) CUGBP1-eIF2 and the
20S proteasome complexes were purified by a combi-
nation of high-performance liquid chromatography-
based chromatography using different ion exchange
columns and size exclusion columns (Figure 2A). The
location of complex 3 within the fractions was moni-
tored by EMSA with the CCUG16 probe. The identity of
the CUGBP1-eIF2 and the 20S proteasome complexes
was determined by mass spectroscopy analysis in the
Protein Chemistry Core Laboratory (Baylor College of
Medicine).
Translation of C/EBP in a Cell-Free Translation
System
Five micrograms of two different preparations of the
CUGBP1-eIF2 complex were added to the rabbit reticu-
locyte system (Promega Corporation, Madison, WI) pro-
grammed with C/EBP mRNA and supplemented with
[35S]methionine. Newly synthesized radioactive C/EBP
proteins were precipitated with anti-C/EBP and the im-
munoprecipitates were resolved by denaturing 10% poly-
acrylamide gel electrophoresis. Proteins were transferred
to membrane and exposed to X-ray film.
EMSA (Gelshift)–Western Assay for the 20S
Proteasome Complex
To determine that the 20S proteasome within complex
3–2 binds to CCUG repeats, cytoplasm from myoblasts
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derived from DM2 patients was separated by ion ex-
change chromatography, and the complex was identi-
fied by EMSA with CCUG16 probe on native 5% gel.
The piece of polyacrylamide gel with the complex was
cut out and loaded on a denaturing 5 to 20% gel.
Proteins were transferred onto a membrane and
probed with antibodies to the components of the 20S
proteasome core.
Transient Transfections
CCTG300 was synthesized as described
23 and cloned
into a pCDNA3.1 vector. CCTG36 and AU42 repeats con-
taining primers with flanking cloning sites were synthe-
sized by Integrated DNA Technologies, Coralville, IA and
cloned into pSUPER expression vector. Plasmids were
transfected into control human myoblasts derived from
unaffected patients and into mouse C2C12 myoblasts
using Amaxa biosynthesis cell line Nucleofector kit. As an
alternative approach, synthetic CCUG16 and AU42 RNAs
were transfected into control human and C2C12 myo-
blasts according to the Amaxa protocol.
Separation of Protein-Protein and RNA-Protein
Complexes
Cytoplasmic extracts from control and DM2 myoblasts
and tissues from wild-type and CCTG transgenic mice
were analyzed as described.17 Briefly, cytoplasmic pro-
teins were loaded on a size exclusion SEC400 column.
The chromatography fractions were divided in portions
Figure 2. Purification of complex 3. A: A diagram showing the strategy for the isolation of the complex. Twenty milligrams of cytoplasmic proteins from livers
of wild-type aged mice were used for the isolation of the high molecular weight complexes. B: Detection of the complex 3 in each step of purification by EMSA/gel
shift assay with CCUG16 RNA. The fractions containing complex 3 and complexes 3–1 and 3–2 are underlined. C: A representative picture showing the analysis
of protein fractions after the second step of purification by UV cross-link with CCUG16 RNA and by Western blotting with antibodies to CUGBP1. A major portion
of complex 3–1 is located in fractions marked with red line. The position of CUGBP1 in the fractions examined by UV cross-link is shown by open circles. D:
Coomassie staining of proteins of complex 3–1 after size exclusion chromatography. The identity of these proteins was determined by mass spectroscopy. E: UV
cross-link analysis of the purified complex. The purified complex was incubated with the CCUG16 probe and examined by UV cross-link assay. The arrow shows
a position of CUGBP1. F: The composition of the purified complex 3–1 determined by Western blotting with antibodies shown on the left. Western blotting
analysis of two preparations of the complex 3–1 is shown. G: The purified complex 3–1 (CUGBP1-eIF2) increases translation of C/EBP in a cell-free translation
system. Two different preparations of the CUGBP1-eIF2 complex were added in the reticulocyte lysate programmed with C/EBP mRNA. Positions of LAP and
LIP isoforms of C/EBP are shown.
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and analyzed by dot-blot hybridization, EMSA, and UV
cross-link with the CAGG16 probe and by Western blot-
ting with antibodies to CUGBP1, eIF2, CRT, and -actin.
Results
CCUG-Containing RNA Is Detected in Both the
Nucleus and Cytoplasm of DM2 Myoblasts
Differences in DM1 and DM2 phenotypes prompted us to
search for specific RNA CCUG-binding proteins that
might be affected in DM2 cells. To identify CCUG-binding
proteins, we initially analyzed the distribution of RNA
CCUG repeats in DM2 myoblasts using several ap-
proaches. Fluorescence in situ hybridization assays with
a CAGG16 probe showed that CCUG-positive signals are
observed in both the nuclei and the cytoplasm of DM2
myoblasts (Figure 1A). This result was unexpected, since
the expanded CCUG repeats are located within the intron
of the ZNF9 gene and should be spliced out before the
entry of ZNF9 mRNA into the cytoplasm. Given this un-
usual distribution of CCUG repeats, we performed addi-
tional studies. Nuclear and cytoplasmic RNA was iso-
lated from control and DM2 myoblasts and used for
Northern blot hybridization with a CAGG16 probe. This
analysis showed approximately equal amounts of CCUG-
positive signals in the nuclear and cytoplasmic RNAs
from DM2 cells. In contrast, in normal cells, a weak signal
was observed in the nuclear but not in the cytoplasmic
RNA (Figure 1B). Although CCUG-containing RNA ap-
peared as a diffuse signal on the gel, EtBr staining of the
same gels showed sharp, distinct bands for ribosomal
RNAs 28S and 18S. Since 28S and 18S RNAs were intact,
we propose that CCUG-positive RNA in DM2 cells mi-
grated as a “smear” band due to formation of intermedi-
ate products of splicing in the nucleus or products of
specific cleavage in the cytoplasm. To confirm the cyto-
plasmic localization of CCUG repeats in DM2 cells, we
performed dot-blot hybridization with these RNAs. As can
be seen in Figure 1C, DM2 myoblasts contained approx-
imately equal amounts of CCUG-positive RNA in the nu-
clear and cytoplasmic RNAs, while in control myoblasts
from unaffected patients, CCUG repeats were detected
only in the nuclear RNA. Increased amounts of RNA
CCUG repeats in the cytoplasm of myoblasts derived
from DM2 patients were later confirmed by high-perfor-
mance liquid chromatography-based techniques. There-
fore, four independent approaches showed that DM2
myoblasts contain RNA CCUG repeats not only in the
nucleus but also in the cytoplasm.
CCUG RNA Interacts with Protein-Protein
Complexes, Amounts of Which Are Increased in
DM2 Myoblasts
To identify proteins that bind to CCUG repeats in the
cytoplasm, we initially analyzed cytoplasmic proteins from
mouse C2C12 myotubes by EMSA with three riboprobes:
CUG8, CCUG8, and CCUG16. We found that, in mouse
myotubes, CUG8 RNA formed a single specific RNA-protein
complex (Figure 1E), which was repressed by non-radio-
active CUG8 and supershifted with antibodies to
CUGBP1 (see Supplemental Figure S1 at http://ajp.
amjpathol.org). On the contrary, CCUG16 RNA formed
three complexes: complex 1, migrating in the position of
CUGBP1-CUG8, complex 2, and complex 3, observed
close to the start of the gel (Figure 1E). The high molec-
ular weight complex 3 interacted specifically with
CCUG16 RNA, since the CUG probe did not form this
complex. To confirm the specificity of the CCUG16 inter-
acting complexes, we included CCUG16 non-radioactive
competitor in the binding reactions. All three CCUG com-
plexes were formed by specific interactions because
addition of non-radioactive CCUG16 RNA inhibited the
formation of these complexes (Figure 1F). Additional
competition experiments revealed that the addition of
CUG8 cold competitor abolished formation of complexes
1 and 2, but did not affect the formation of complex 3 (see
Supplemental Figure S1 at http://ajp.amjpathol.org).
These data suggested that complex 3 specifically recog-
nizes CCUG RNA. The addition of antibodies to CUGBP1
to the binding reaction resulted in a supershift of com-
plexes 1 and 2, indicating these complexes contained
CUGBP1 (Figure 1F). Because CUGBP1 containing com-
plex 2 did not interact with CCUG8 RNA (Figure 1E), we
asked if this lack of the interaction was due to the inability
of CUGBP1 to bind to CCUG8 RNA, despite the homol-
ogy between CUG and CCUG repeats (Figure 1D), or if
the interaction was blocked by other proteins within cel-
lular extracts. To address these questions, homogenous
CUGBP1 fused with maltose-binding protein (MBP-
CUGBP1) was initially examined by UV cross-link assays
with CUG8, CCUG8 and CCUG16 probes. Figure 1G
shows that MBP-CUGBP1 did not bind to CCUG8 RNA,
while the binding to CUG8 and CCUG16 RNAs was
strong. To test if purified CUGBP1 binds to long CCUG
repeats, we performed UV cross-link with RNA containing
300 CCUG repeats. Figure 1H shows that the purified
CUGBP1 binds to the long CCUG repeats. Therefore,
these studies suggest that CUGBP1 binds to RNAs con-
taining 16 and more CCUG repeats.
To determine the amount of CCUG-binding com-
plexes in DM2 myoblasts, we examined cytoplasmic
protein extracts from control human myoblasts and
from myoblasts derived from DM2 patients by EMSA
with the CCUG16 riboprobe. As shown in Figure 1I,
several CCUG-protein complexes were formed in con-
trol myoblasts, including complex 3, similar to that
observed in C2C12 extracts. The pattern of RNA bind-
ing proteins in DM2 cytoplasm was quite different. The
amount of complex 3 was increased in the cytoplasm
of DM2 myoblasts compared with normal myoblasts,
while complexes of smaller sizes were reduced or un-
detectable (Figure 1I). Given the increase of complex 3
in the cytoplasm of DM2 myoblasts, we suggested that
this complex might be involved in the development of
DM2 pathology. Therefore, we performed further isola-
tion and characterization of complex 3.
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CCUG-Binding Complex 3 Consists of Two
Independent Complexes: 20S Catalytic Core
Complex of the Proteasome and the
Translational Complex CUGBP1-eIF2
We initially tried to isolate complex 3 from the cytoplasm
of C2C12 myotubes, but these experiments were only
partially successful. The isolated complex was detect-
able by EMSA approach; however, amounts of proteins
within the complex were not sufficient for mass spectros-
copy. To find a better source for the isolation of complex
3, we examined a number of tissues by EMSA with
CCUG16 probe. We observed that complex 3 was abun-
dant in cytoplasmic extracts from the livers of old mice
(data not shown). Therefore, we have purified multipro-
tein complexes from the livers of old mice using high-
performance liquid chromatography-based techniques.
The general procedure for the purification of the com-
plexes is shown in Figure 2A. To monitor complex 3
during purification, EMSA/gel shift with a CCUG16 probe
was applied. A typical picture of gel shift assays at each
step of purification is shown in Figure 2B. In the course of
these studies, we surprisingly found that CUGBP1 colo-
calized with complex 3 on the first three steps of the
purification, but was separated by chromatography on
the CHT1 column. As an example of this colocalization,
Figure 2C shows examination of chromatography frac-
tions after the second step of purification on the UnoQ
column by UV cross-link and Western blotting analysis.
As can be seen, several RNA binding proteins co-purified
with complex 3 (Figure 2C, UV cross-link), one of which
was CUGBP1 (Figure 2C, Western). However, chromatog-
raphy on the CHT1 column separated a CUGBP1 contain-
ing complex (complex 3–1) and an additional complex
(complex 3–2), which was later identified as the complex
containing the 20S proteasome.
Further separation of complex 3–1 by size exclusion
chromatography and analysis of its protein composition
revealed that this complex is identical to one identified in
the liver17 and in human myotubes.18 Figure 2D shows a
Coomassie blue stain of complex 3–1. Identity of the
protein components and the RNA binding activity of the
purified complex 3–1 were further examined by mass
spectroscopy, UV cross-linking, and Western blotting as-
says. The purified complex 3–1 contained three RNA
binding proteins, one of which migrated in the position of
CUGBP1 (Figure 2E). Examination of the complex by
mass spectroscopy and Western blotting showed that
this complex contains CUGBP1, eIF2, eIF2, CRT,
eR99, and GRP78 (Figure 2, D and F). To determine
whether the purified complex 3–1 possesses translational
activity similar to the previously identified CUGBP1-eIF2
complex,17 we examined the effects of the purified com-
plex on the translation of C/EBP mRNA in a cell-free
translational system. Figure 2G shows that the purified
complex 3–1 (subsequently referred to as CUGBP1-eIF2)
increased translation of both isoforms of C/EBP, LAP,
and LIP. Thus, the composition and biological activity of
complex 3–1 are identical to those previously described
for the CUGBP1-eIF2 complex.
The Activity of the CUGBP1-eIF2 Complex Is
Elevated in DM2 Myoblasts
To determine the amount of the CUGBP1-eIF2 complex in
DM2 patients, CUGBP1 was immunoprecipitated from
control and DM2 myoblasts and the CUGBP1 IPs were
probed with antibodies to components of the CUGBP1-
eIF2 complex. Figure 3A shows that eIF2, eIF2 and
eR99 are observed in CUGBP1 IPs from DM2 myoblasts,
while these proteins are low or not detectable in CUGBP1
IPs from myoblasts derived from unaffected patients.
Since CUGBP1 regulates translation of p21 and C/EBP
mRNAs,16–18 we also examined if binding of the
CUGBP1-eIF2 complex to these mRNAs is elevated in
DM2 myoblasts. CCUG16 RNA and c-fos (AU-rich RNA
probe) were included as positive and negative controls
respectively. EMSA assay showed that complex 3, con-
taining CUGBP1-eIF2, strongly interacts with CCUG16
and C/EBP RNAs and the binding of the complex to
these RNAs is significantly increased in DM2 myoblasts
(Figure 3B). The interaction of the complex with p21
mRNA is weak and is slightly increased in DM2 myo-
blasts. The interaction of the complex with tested RNAs
was specific, because the CUGBP1-eIF2 complex did
not interact with the c-fos RNA probe.
We next examined the levels of CUGBP1 and the levels
of its translational targets in cultured myoblasts derived
from DM2 patients and in mature skeletal muscle from
DM2 patients. Western blotting analysis with cultured
myoblasts from DM2 patients showed that CUGBP1 is
elevated in the cytoplasm of DM2 myoblasts (Figure 3C).
DM2 myoblasts also accumulated low mobility CUGBP1
isoforms migrating in the position of hyperphosphory-
lated forms of CUGBP1. These alterations are consistent
with previous observations, which showed that the inter-
action of CUGBP1 with eIF2 is mainly regulated by phos-
phorylation of CUGBP1.17,18 We have previously shown
that CUGBP1 increases translation of MEF2A and
C/EBP mRNAs.13,17 Examination of the protein levels of
these translational targets of CUGBP1 revealed that
amounts of both proteins are increased in cultured myo-
blasts derived from DM2 patients (Figure 3C). We next
examined if these translational targets of CUGBP1 were
increased in mature skeletal muscle of DM2 patients.
Western blotting showed that, like in cultured myoblasts,
protein levels of MEF2A and C/EBP are also increased
in DM2 muscle biopsies (Figure 3D). These data are
consistent with the hypothesis that accumulation of the
CUGBP1-eIF2 complex in DM2 patients changes trans-
lation of MEF2A and C/EBP.
CUGBP1 Is Associated with Cytoplasmic
CCUG Repeats in DM2 Cells, in CCTG
Transgenic Mice and in Cells Transfected with
Vector-Expressing Long CCUG Repeats
The presence of CCUG repeats in the cytoplasm of DM2
myoblasts and the binding of CUGBP1-eIF2 to CCUG
RNA prompted us to test if CUGBP1-CCUG complexes
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exist in the cytoplasm of DM2 myoblasts. Cytoplasmic
extracts from control and DM2 myoblasts were separated
by high-performance liquid chromatography on SEC400
column and examined by Western blotting with antibod-
ies to CUGBP1. In myoblasts from unaffected patients,
the major portion of CUGBP1 migrated as a free protein
or as a protein within low MW complexes; however, in
DM2 myoblasts, significant amounts of CUGBP1 were
translocated into the region containing high MW com-
plexes (Figure 4A). Examination of CCUGn RNA distribu-
tion within the fractions showed that CUGBP1 colocalized
with CCUGn repeats (Figure 4A). Such co-localization
suggests that CUGBP1 is shifted to the high MW com-
plexes due to binding to CCUG repeats. This shift was
specific because CCUG repeats did not change the lo-
calization of -actin (Figure 4A).
We performed additional studies, using tissue culture
and a CCTG TR mouse model (see Materials and Meth-
ods) to characterize interactions of CUGBP1 complexes
with the CCUG repeats. To this end, we used two sys-
tems: C2C12 myoblasts transfected with plasmid ex-
pressing 300 CCUG repeats, and the livers from TR mice
expressing non-coding CCUG121 RNA. Cytoplasmic ex-
tracts from C2C12 myoblasts transfected with an empty
vector or with long CCTG repeats were separated by size
exclusion chromatography, and CUGBP1 and eIF2
were examined in the chromatography fractions using UV
cross-link assay (for CUGBP1) and Western blotting (for
CUGBP1 and eIF2). As shown in Figure 4B, in C2C12
myoblasts transfected with an empty vector, CUGBP1
and eIF2 were located in the regions containing free
proteins and low MW complexes. However, in C2C12
myoblasts expressing RNA CCUG300, significant amounts
of CUGBP1 and eIF2 were shifted to the fractions con-
taining high molecular weight complexes. CUGBP1 RNA-
binding activity was also shifted to the fractions contain-
ing high MW complexes (Figure 4B, UV cross-link). eIF2
and CRT (data for CRT not shown) co-localized with
CUGBP1 in C2C12 myoblasts, transfected with an empty
vector, and they were shifted together with CUGBP1 into
fractions containing high MW complexes in CCUG-ex-
pressing C2C12 myoblasts (Figure 4B, Western). Blot
hybridization of RNA isolated from the chromatography
fractions with a CAGG16 probe showed that CUGBP1-
eIF2 complexes are located in the fractions containing
CCUG RNA (Figure 4B, hybridization). Thus, ectopically
expressed mutant CCUG RNA binds to the CUGBP1-
eIF2 complex.
We next studied the effects of CCUG repeats on
CUGBP1 in the cytoplasm of CCTG TR mice. Since ex-
pression of CUGBP1 is increased in DM2 (Figure 3C), we
first examined protein levels of CUGBP1 in CCTG TR
mice and found a threefold elevation of CUGBP1 in the
livers of these mice (Figure 4C). Because DM2 myoblasts
have increased amounts of complex 3 (Figure 1I), we
examined this complex by size exclusion chromatogra-
phy in wild-type and in CCTG TR mice. EMSA analysis of
the chromatography fractions demonstrated that wild-
type livers have limited amounts of complex 3. However,
the complex was abundant in the cytoplasm of CCTG TR
mice (Figure 4D, top). Examination of the gel filtration
fractions by Western blotting showed that CUGBP1 and
eIF2 in wild-type livers were located in fractions contain-
ing free proteins and low MW complexes. Quite a differ-
ent distribution of these proteins was observed in CCTG
TR mice. We found that more than 50% of CUGBP1 and
Figure 3. DM2 muscle cells contain high amounts of the CUGBP1-eIF2 complex. A: The amount of CUGBP-eIF2 complex is increased in DM2 myoblasts. CUGBP1
was immunoprecipitated from the cytoplasmic extracts of normal control and DM2 myoblasts and examined by Western blotting with antibodies to eIF2, eIF2,
and eR99. IgG; signals of the heavy chains of IgGs. B: The binding of complex 3 to CCUG16 and C/EBP mRNA is increased in DM2 myoblasts. EMSA was
performed with C/EBP, p21, CCUG16, and c-fos probes with cytoplasmic proteins from myoblasts derived from unaffected patients (normal) and from patients
with DM2. The position of the CUGBP1-eIF2 complex is shown by the arrow. C: Protein levels of CUGBP1 and its translational downstream targets, MEF2A and
C/EBP, are increased in myoblasts from DM2 patients. Western blotting analyses of myoblasts from unaffected (normal) and DM2 patients with antibodies against
CUGBP1, MEF2A, and C/EBP are shown. Membranes were re-probed with antibodies against -actin. Low-mobility CUGBP1 isoforms migrating in the positions
of hyperphosphorylated CUGBP1 are shown by red arrows. D: Protein levels of MEF2A and C/EBP are increased in DM2 muscle biopsies. Cytoplasmic (for
CUGBP1) and nuclear extracts (for MEF2A and C/EBP) were examined by Western blotting with antibodies shown on the right. The membranes were re-probed
with anti--actin.
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eIF2 were shifted to fractions containing very high MW
complexes. Blot hybridization of RNA from the chroma-
tography fractions showed that the CUGBP1-eIF2 com-
plex co-localized with CCUGn RNA in the livers of trans-
genic mice. Examination of -actin in the fractions shows
that the translocation of CUGBP1 and eIF2 was specific,
since the location of -actin in size exclusion fractions
was not changed on expression of CCUGn RNA. Thus,
these studies demonstrated that the mutant CCUG re-
peats target complex 3, which consists of CUGBP1-eIF2
and 20S proteasome (see below).
The 20S Catalytic Core Complex of the
Proteasome Interacts with CCUG Repeats
Chromatography on the CHT1 column separated the
CUGBP1-eIF2 complex (3–1) from complex 3–2 (Figure
2). CUGBP1 and eIF2 were no longer detectable within
complex 3–2 suggesting that this complex is a new
CCUG-binding complex. The purified complex 3–2 was
subjected to mass spectroscopy, which identified five
subunits of the 20S catalytic core complex of the protea-
some within this complex (Figure 5A). To confirm the
identity of the proteins, the purified complex was tested
by Western blotting with antibodies to subunits of the 20S
proteasome. We found that 2, 4, and 7 subunits were
detected within the complex, while HuR (control) was not
observed in the complex (Figure 5B). In addition to 20S
proteasome, mass spectroscopy analysis identified BiP,
Hsp70, Disulfide Isomerase, isovaleryl coenzyme A de-
hydrogenase and delta aminolevulinate dehydrogenase
(data not shown). To examine if Hsp70 is associated with
the proteasome in vivo, we immunoprecipitated the pro-
teasome from the cytoplasmic extracts of livers from old
Figure 4. CUGBP1 is associated with the expanded CCUG repeats in the cytoplasm of DM2 myoblasts and in cytoplasm of livers of CCTG TR mice. A: CUGBP1
is bound to the mutant CCUG RNA in cytoplasm of DM2 myoblasts. Cytoplasmic proteins from myoblasts derived from unaffected (normal) patients and patients
with DM2 were fractionated by gel filtration. Western blot analysis of gel filtration fractions was performed with antibodies to CUGBP1 and -actin. RNA from
the same fractions was examined by blot hybridization with CAGG16 probe. B: Ectopically expressed CCUG300 RNA binds to the CUGBP1-eIF2 complex.
Cytoplasmic proteins from C2C12 myoblasts transfected with an empty vector (control) and from cells transfected with a plasmid expressing CCUG300 were
fractionated on size exclusion column SEC400. Optical density (OD280) profiles of gel filtrations are shown on the top. Gel filtration fractions were examined by
UV cross-link with CCUG16 probe, by Western blotting with CUGBP1 and eIF2 antibodies, and by blot hybridization with CAGG16 probe (CCUG). The position
of the CUGBP1-eIF2 complex associated with the CCUG repeats is shown below. C: CUGBP1 levels are increased in the livers of CCTG-transgenic mice. Western
blot analyses of cytoplasmic liver extracts from three wild-type (WT) and three CCTG TR mice were performed with antibodies to CUGBP1 and -actin. Bar graphs
show the levels of CUGBP1 as ratios to -actin. D: Complex 3 is abundant in the livers of CCTG-transgenic mice. Cytoplasmic proteins from wild-type and CCTG
TR mice were fractionated on SEC400 column. Top image shows EMSA with CCUG16 probe, which located complex 3 within gel filtration fractions. The positions
of complex 3 and free probe are shown by arrowheads. Western: Gel filtration fractions were analyzed by Western blotting with antibodies to CUGBP1, eIF2
and -actin (control). Bottom image shows results of blot hybridization of the fractions with CAGG16 probe.
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mice with antibodies to the 4 subunit, and probed these
4 IPs with antibodies to 2 and Hsp70. Figure 5C shows
that Hsp70 is associated with the subunits 2 and 4 of
the proteasome. It has been shown that Hsp70 might be
associated with the proteasome through misfolded pro-
teins, a process that is regulated by ATP.24 Therefore, we
examined if the addition of ATP releases Hsp70 from the
proteasome complex. ATP was added to the protein ex-
tracts, the proteasome was precipitated with antibodies
to 4, and the presence of Hsp70 was determined by
Western blot. As seen in Figure 5C, ATP did not release
Hsp70 from the complex. Thus, Hsp70 seems to be as-
sociated with the proteasome via specific interactions,
which do not involve unfolded proteins. It is currently
unclear whether the remaining proteins are associated
with the 20S proteasome, or whether they represent an
additional complex interacting with RNA CCUG16. Thus,
the major component of the purified CCUG-binding pro-
tein complex 3–2 is the 20S proteasome.
To further determine relationships of the complex 3–2
with CCUG repeats, we asked if complex 3–2 directly
interacts with RNA CCUG repeats. Since the 20S protea-
some is part of the larger 26S complex, we have also
analyzed commercially available human 20S and 26S
proteasomes (Biomol International, LP) by UV cross-link
with RNA CCUG16 riboprobe. The results of these exper-
iments showed strong binding of several proteins located
in the position of the purified 20S proteasome (Figure
Figure 5. Complex 3–2 contains the 20S catalytic core of the proteasome. A: Coomassie staining of the complex 3–2 after CHT1 column. Identity of proteins within
the complex was determined by mass spectroscopy. Positions of protein markers are shown on left. B: The purified CCUG-binding complex 3–2 contains 20S
proteasome. The purified complex was tested by Western blot assay with antibodies against subunits 2, 4 and 7 of the 20S proteasome. Cytoplasmic protein
extract from C2C12 myotubes (cyto) and anti-HuR were used as controls. C: Hsp70 protein is associated with the proteasome complex. Proteasome complex was
immunoprecipitated from the cytoplasm of old mouse livers by Abs to the 4 subunit of the 20S proteasome and Hsp70 was examined in this IP by Western
blotting. Third lane shows Hsp70 in the 4-IP from cytoplasmic liver extract treated with ATP. IgG; heavy chains of IgGs used for IP. The filter was re-probed
with Abs to 2 and 4 subunits of the 20S proteasome. D: Complex 3–2 directly binds to RNA CCUG repeats. Left image: UV cross-link assay of the 20S and 26S
proteasomes (BioMol International, LP) and the complex 3–2 with RNA CCUG16. Right image shows the UV cross-link of these complexes with C/EBP RNA probe
(negative control). E and F: Complex 3–2 contains proteins of 20S proteasome. Proteins were fractionated by ion exchange chromatography and fractions were
examined by gel shift assay with CCUG16 probe (upper) and by Western blot with antibodies against 2, 4, 6, and 7 subunits of the 20S proteasome (middle).
The fragment of gel containing the complex 3–2 was cut out, loaded onto a 4 to 20% polyacrylamide gel and examined by Western blotting with antibodies against
2, 4 and 7 subunits of the 20S proteasome. G: RNA CCUG repeats bind with the 20S core complex in DM2. FISH hybridization with CAGG16 probe (green)
was performed using myoblasts from DM2 patients and normal control myoblasts following immunofluorescent analyses (top) with antibodies against the 4
subunit of the 20S proteasome. The positions of the proteasome associated with CCUG repeats in the cytoplasm are shown by arrows.
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5D). Additional CCUG RNA binding protein was ob-
served in the position of 60 kd in both the 26S protea-
some (BioMol International, LP) and the purified CCUG-
binding complex 3–2. The interaction of the proteasome
complex with CCUG repeats was specific, since a similar
UV cross-link assay with the C/EBP riboprobe showed
no detectable interactions (Figure 5D, right image). Thus,
these data show that purified complex 3–2 and commer-
cially available 20S and 26S proteasomes directly inter-
act with RNA CCUG repeats.
To obtain additional evidence that the 20S proteasome
within complex 3–2 binds to CCUG repeats, complex 3–2
was separated by ion exchange chromatography and
localized within fractions by EMSA assay with CCUG16
probe (Figure 5E). The localization of individual compo-
nents of the 20S proteasome was determined by Western
blotting with antibodies against the 20S core complex. As
can be seen (Figure 5F), fractions possessing CCUG-
binding activity contain 2, 4, 6, and 7 subunits of the
20S catalytic core of the proteasome. This co-localization
suggests that the 20S proteasome binds to CCUG
repeats. To verify this co-localization, the region of the
gel containing complex 3–2, was cut out, proteins were
resolved by denaturing gel, transferred on the mem-
brane and probed with antibodies to components of
the 20S proteasome (Figure 5F; Gelshift & Western). As
seen, the subunits 2, 7, and 4 are the components
of complex 3–2.
To investigate interactions of the 20S complex with
RNA CCUG repeats in DM2 myoblasts, we have applied
a combination of FISH assay with CAGG probe and im-
munofluorescence with antibodies against the 4 sub-
units of the 20S core proteasome complex. Results of
these experiments revealed that the 20S proteasome is
associated with RNA CCUG repeats in the cytoplasm of
DM2 myoblasts (Figure 5G). Taken together, these stud-
ies demonstrated that RNA CCUG repeats interact with
the 20S proteasome and that expanded CCUG repeats
are associated with the 20S proteasome in cytoplasm of
DM2 myoblasts.
Inhibition of Protein Degradation in DM2
Myoblasts
Given the association of the 20S proteasome complex
with CCUG repeats in DM2 myoblasts (Figure 5G), we
suggested that this association might affect the
amounts and activities of the 20S proteasome in DM2
myoblasts. To test this suggestion, we examined the
20S proteasome in DM2 myoblasts and determined the
stability of proteins that are degraded by the protea-
some. Because Hsp70 is a part of the 20S proteasome
complex that binds to the CCUG repeats, the protea-
some was immunoprecipitated with antibodies to 4
from cytoplasmic extracts of control and DM2 myo-
blasts, and the IPs were probed with antibodies to
Hsp70. Figure 6A shows that Hsp70 was observed in
the proteasome complex in DM2 myoblasts, while nor-
mal myoblasts do not have detectable amounts of
Hsp70 in the proteasome. As mentioned above, the
association of Hsp70 with the proteasome might be
mediated through misfolded proteins and this type of
association might be disrupted by ATP.24 Therefore,
ATP was added to the protein extracts before precip-
itation of the proteasome. We found that the addition of
ATP to the protein extracts slightly reduced the asso-
ciation of Hsp70 with the proteasome; however, a sig-
nificant portion of Hsp70 remains in the complex.
Therefore, a significant portion of Hsp70 is associated
specifically with the 20S proteasome, but not through
misfolded proteins. Given the association of the 20S
proteasome complex with CCUG repeats in DM2 (Fig-
ure 5G), we examined levels of short-lived proteins
such as p21, c-myc and CUGBP1 by Western blotting.
These studies showed that these three proteins are
elevated in myoblasts derived from DM2 patients (Fig-
ure 6B). To examine if alterations in the activity of the
proteasome in DM2 myoblasts are involved in the ele-
vation of the short-lived proteins, we have used the
proteasome inhibitor MG132. In control myoblasts de-
rived from unaffected patients, inhibition of the protea-
some by MG132 significantly increased protein levels
of c-myc and p21, while the effect of MG132 on
CUGBP1 levels was minor, perhaps, due to the rela-
tively longer half-life of CUGBP1 (3.5 hours). On the
contrary, incubation of DM2 myoblasts with MG132 did
not lead to an elevation of these proteins (Figure 6C).
We suggest that the lack of MG132-dependent stabili-
zation of these proteins in DM2 myoblasts reflects the
fact that the biological functions of the proteasome are
already inhibited by titration to the expanded CCUG
repeats.
An important step of proteasome-mediated degra-
dation of proteins is the formation of ubiquitin conju-
gates of the degraded proteins.25 Therefore, we looked
at ubiquitin conjugates in DM2 myoblasts. Control and
DM2 myoblasts were treated with MG132 for 4 hours
and proteins were examined by Western blotting with
antibodies to ubiquitin. Figure 6D shows that treatment
of control myoblasts with MG132 leads to increased
amounts of high MW ubiquitin-protein conjugates. In
contrast to normal myoblasts, untreated DM2 myo-
blasts already contained large amounts of ubiquitin-
protein conjugates and the treatment with MG132 only
slightly increased amounts of these conjugates. Free
ubiquitin was not detectable in human myoblasts under
sensitivity of our assay. To determine whether DM2
myoblasts accumulate ubiquitin conjugates of specific
proteins, p21 was immununoprecipitated from un-
treated and treated control and DM2 myoblasts, and
p21 IPs were probed with antibodies to ubiquitin. In
control myoblasts treated with MG132, a mono-ubiq-
uitin form of p21, migrating in the position of 30 kd, was
dramatically increased. In contrast, untreated and
MG132 treated DM2 myoblasts contained mono- and
polyubiquitinated forms of p21 (Figure 6E). These data
show that proteasome function is inhibited in DM2
myoblasts and that this inhibition leads to the accumu-
lation of ubiquitin-protein conjugates.
We next compared the half-life of c-myc, p21 and
CUGBP1 in control and in DM2 myoblasts. Protein
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synthesis was blocked by cycloheximide and protein
levels of c-myc, p21 and CUGBP1 were analyzed at
different time points after addition of cycloheximide. As
shown in Figure 6, F and G, stability of the examined
proteins was significantly higher in DM2 myoblasts
than in control myoblasts derived from unaffected pa-
tients. Thus, the stability of short-lived proteins is in-
creased in DM2 myoblasts. These data are consistent
with the hypothesis that CCUG-mediated sequestration
of the 20S proteasome leads to impaired turnover of
the proteins in DM2 myoblasts.
Expression of CCUG Repeats in Normal
Myoblasts Alters Translation and Degradation of
Proteins Similar to Alterations Observed in DM2
Myoblasts
Given the observations that DM2 myoblasts have altered
translation of CUGBP1 targets and that stability of short-
lived proteins is increased in DM2 myoblasts, we exam-
ined if ectopic expression of RNA CCUG repeats in
C2C12 myoblasts and in human myoblasts from unaf-
Figure 6. Proteasome activity is inhibited in DM2 myoblasts leading to the increased stability of short-lived proteins in DM2. A: Hsp70–20S proteasome complex
is increased in DM2 myoblasts. Proteasome was immunoprecipitated from myoblasts derived from unaffected (N) and DM2 patients and probed with Abs to Hsp70
(upper panel). Two middle panels show examination of 2 and 7 subunits of the 20S proteasome within 4 IPs. Bottom panel shows Coomassie staining of heavy
chains of immunoglobulins (IgGs) used for IP. First lane in all panels is a control with preimmune serum. Fourth lane in all panels shows the results of IP-Western
with cytoplasmic extract from DM2 myoblasts containing ATP. B: Western blot analyses of control (N) and DM2 myoblasts with antibodies to p21, c-myc and
CUGBP1. Protein loading was verified by Western blotting with antibodies against -actin. C: The activity of proteasome is inhibited in DM2 myoblasts. Control
and DM2 myoblasts were treated with MG132 and protein levels of p21, c-myc and CUGBP1 were examined. -actin or cross-reactive molecule (CRM) signals
show equal protein loading. D: Amounts of ubiquitin-protein conjugates are increased in DM2 myoblasts. Total protein extracts from untreated control and DM2
myoblasts and myoblasts treated with MG132 were examined by Western blotting with antibodies to ubiquitin. Bottom image shows a Coomassie staining of the
filter. E: Amounts of p21-Ub conjugates are increased in DM2 myoblasts. Upper image shows levels of p21 in extracts used for detection of ubiquitin-p21
conjugates. Middle image: p21 was immunoprecipitated from control myoblasts derived from unaffected patients and from DM2 myoblasts and p21 IPs were
probed with antibodies to ubiquitin. Bottom image shows Coomassie stain of heavy chains of immunoglobulins (IgG) after analysis of p21-IPs. F: Stability of p21,
c-myc and CUGBP1 proteins is increased in DM2 myoblasts. Control and DM2 myoblasts were treated with cycloheximide to inhibit protein translation. Proteins
were analyzed by Western blotting assay with antibodies against p21, c-myc and CUGBP1. 20 g of proteins from DM2 myoblasts and 50 g of proteins from
control myoblasts were used to compensate for the increase of p21, c-myc and CUGBP1 in DM2. Membranes were re-probed with anti--actin to verify protein
loading. G: Protein levels of p21, c-myc, and CUGBP1 were calculated as ratios to -actin in control (red) and DM2 (blue) myoblasts. The picture shows percent
(y axis) of each protein at 1, 2, and 4 hours (x axis) after addition of cycloheximide relative to 0 time point.
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fected patients would cause similar alterations. Examina-
tion of CCUG repeats in C2C12 myoblasts transfected
with CCUG36 by FISH assay showed that, similar to the
distribution of the CCUG repeats in DM2 myoblasts (Fig-
ure 1), CCUG repeats were detected in the cytoplasm
and in the nucleus (Figure 7A).
We next examined if the expression of CCUG re-
peats in myoblasts from unaffected patients increases
the translational activity of CUGBP1 toward a known
target, C/EBP. A single C/EBP mRNA produces
mainly two isoforms, liver enriched activator protein
(LAP) and liver enriched inhibitory protein (LIP), and
the CUGBP1-eIF2 complex increased translation of
both these isoforms in an in vitro translation system
(Figure 2G). Western blotting experiments showed that
the levels of LAP and LIP isoforms were undetectable
in human normal myoblasts, transfected with control
AU42 RNA, while normal myoblasts transfected with
CCUG RNA had increased levels of LAP and LIP (Fig-
ure 7B). Because LIP can be produced only by alter-
native translation from the third AUG codon,26 these
data show that the induction of C/EBP isoforms by
Figure 7. Expression of CCUG RNA repeats in control myoblasts from unaffected patients and from C2C12 myoblasts increases the levels of C/EBP isoforms
and stabilizes c-myc, p21 and CUGBP1 proteins. A: Transfected CCUG RNA is located in nuclei and in cytoplasm. Upper. C2C12 myoblasts were transfected with
a plasmid expressing CCUG36 repeats. FISH hybridization with CAGG16 probe (green) was performed. Cytoplasmic CCUG RNA is shown by arrows. Bottom
images show a merge of nuclei stained with DAPI (blue) and CCUG RNA. B: Protein levels of C/EBP, p21, c-myc and CUGBP1 are increased in human primary
myoblasts derived from unaffected patients transfected with RNA CCUG repeats. Western blotting was performed with total protein extracts isolated from control
human myoblasts transfected with RNA CCUG16 and with control AU42 RNA. Un; protein extracts from un-transfected cells. C: CCUG repeats increase the half-life
of p21, c-myc and CUGBP1. Control human myoblasts were transfected with control AU-rich RNA (AU42) and CCUG16 RNA, protein synthesis was blocked by
cycloheximide and protein levels of p21, c-myc, CUGBP1 and C/EBP were determined. The bottom part shows a similar experiment in mouse C2C12 myoblasts
containing higher levels of C/EBP isoforms LAP and LIP. D: Bar graphs show the half-life of the proteins calculated as a percentage of the 0 time point. E: A
hypothetic model suggesting the role of RNA CCUG repeats in the disruption of protein synthesis and protein degradation in DM2 muscle.
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CCUG RNA is mediated through translational mecha-
nisms. Analysis of C/EBP stability in the presence of
CCUG repeats confirmed this conclusion (Figure 7C).
We next determined the levels of short-lived proteins in
human myoblasts from unaffected patients transfected
with CCUG repeats. We found that the transient expres-
sion of CCUG repeats increased protein levels of c-myc,
CUGBP1 and p21 in normal myoblasts (Figure 7B). Ex-
amination of the half-lives of c-myc, p21 and CUGBP1 in
normal myoblasts transfected with AU42 RNA and in cells
expressing CCUG repeats revealed that CCUG repeats
stabilized these proteins (Figure 7, C and D). To verify if
the CCUG-mediated induction of C/EBP isoforms (LAP
and LIP) is mediated through a translational mechanism,
we tested whether the inhibition of proteasome activity
contributes to the increase of C/EBP isoforms. We found
that myoblasts from unaffected patients contain very low
amounts of LAP and LIP, while LAP and LIP levels were
increased in the presence of CCUG repeats. Our data
show that, in human myoblasts, LAP and LIP are relatively
stable proteins, which were reduced at 4 hours after
inhibition of protein synthesis (Figure 7C). Since control
human myoblasts express low amounts of LAP and do
not express LIP, we also examined the stability of C/EBP
isoforms in C2C12 myoblasts that express both LAP and
LIP. We found that, in C2C12 myoblasts, LAP and LIP
were more stable and were not affected by inhibition of
protein synthesis within 4 hours. Similar to human myo-
blasts from unaffected patients, expression of CCUG
repeats in C2C12 myoblasts increased amounts of both
isoforms of C/EBP but did not affect the half life of these
isoforms. Taken together, these data show that accumu-
lation of CCUG repeats in normal myoblasts leads to
alterations in the translation of CUGBP1 targets and in
stabilization of proteins that are degraded by protea-
some. These alterations mimic changes observed in DM2
myoblasts and confirmed that the expansion of CCUG
repeats in DM2 myoblasts is responsible for the alter-
ations in protein turnover (Figure 7E).
Discussion
CCUG Repeats Inhibit Biological Activities of the
20S Proteasome Complex
A number of observations suggest that pathological al-
terations in DM1 and DM2 are caused by accumulation of
RNA CUG (DM1) and CCUG (DM2) repeats. In DM1,
soluble CUG repeats (outside of intranuclear foci) in-
crease the protein levels of CUGBP1, affecting cytoplas-
mic (translation) and nuclear (splicing) functions of
CUGBP1. Here we present evidence showing that, in
DM2 patients, CCUG repeats alter protein degradation
and protein translation through binding to cytoplasmic
multiprotein complexes. We have identified a transla-
tional CUGBP1-eIF2 complex and a complex containing
the 20S catalytic core of the proteasome as direct targets
of the CCUG repeats. Identification of the 20S protea-
some complex as a complex that interacts with RNA
CCUG repeats was quite surprising and prompted us to
examine the ability of commercially available proteasome
to interact with RNA containing CCUG repeats. We found
that the interaction of the purified proteasome complex
and commercially available proteasomes with RNA
CCUG repeats is specific since these complexes do not
interact with control RNA (Figure 5D). Although precise
mechanisms of the interactions of the proteasome with
CCUG repeats are not known, our UV cross-link study
suggests that this interaction might be direct. Among
several additional proteins within the proteasome com-
plex, we have observed a molecular chaperone Hsp70.
We found that a major portion of Hsp70 is associated with
the 20S proteasome complex independent of binding of
unfolded proteins. Intranuclear inclusions containing pro-
teasome are found in polyglutamine disorders27; however,
in polyglutamine diseases the proteasome complexes inter-
act with misfolded glutamine-containing proteins. HSP40,
ubiquitin and the 20S core complex of the proteasome have
also been identified within the inclusions of the brains of
mice expressing RNA CGG repeats.28 Data presented in
this manuscript suggest that RNA CCUG repeats directly
bind to the proteasome in DM2 myoblasts and inhibit pro-
teasome function.
CCUG Repeats Interact with the CUGBP1-eIF2
Complex and Affect Translational Targets of the
Complex
Another complex interacting with CCUG repeats is the
translational CUGBP1-eIF2 complex. CUGBP1 promotes
cap-dependent translation through interaction with the
eukaryotic initiation complex eIF2.17 We have found that
the CUGBP1-eIF2 complex binds to the mutant CCUG
repeats in the cytoplasm of DM2 myoblasts, in the livers
of CCTG transgenic mice and in C2C12 myoblasts that
ectopically express CCUG300. Consistent with the trans-
lational activity of the CUGBP1-eIF2 complex, the levels
of CUGBP1-dependent translational targets, such as
MEF2A and C/EBP, are increased in primary myoblasts
and in mature muscle biopsies derived from patients with
DM2. This result suggests that the increase of CUGBP1 in
the cytoplasm of DM2 muscle cells might misregulate
translation of additional unknown mRNAs, regulated by
CUGBP1.
Cytoplasmic CCUG Repeats Cause Alterations
in the Protein Turnover
RNA CCUG repeats in DM2 are located within intron 1 of
ZNF9 pre-mRNA, which should be spliced out before
export of ZNF9 mRNA from the nucleus to the cytoplasm.
Surprisingly, we have observed significant amounts of
CCUG repeats in the cytoplasm of DM2 myoblasts. Since
splicing of ZNF9 is not affected in DM2 patients,29 we
hypothesize that CCUG repeats in the cytoplasm of DM2
myoblasts might be the products of the degradation of
the CCUG expansion. Consistent with cytoplasmic local-
ization of the CCUG repeats, CCUG-binding multiprotein
complexes were detected in the cytoplasm of DM2 myo-
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blasts. Our experiments with induced expression of
CCUG repeats in myoblasts from unaffected patients and
in mouse C2C12 myoblasts demonstrated the accumu-
lation of CCUG repeats in the cytoplasm and in the nu-
clei. We also observed mutant CCUGn in the cytoplasm
of the livers of CCTG transgenic mice. The accumulation
of CCUG repeats alters the translation of the targets of
the CUGBP1-eIF2 complex and increases the stability of
c-myc and p21, which are targets of proteasome. In
conclusion, our data suggest that expression of ex-
panded CCUG repeats and their accumulation in the
cytoplasm of DM2 muscle cells alter the biological func-
tions of the CUGBP1-eIF2 and 20S core complexes, af-
fecting global protein turnover.
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